Cardiogenic Shock
Conditions
Brief summary
• Change in left ventricular outflow tract velocity time integral measured by Doppler echocardiography from baseline to 72h after initiation ECMO or before cessation of ECMO support, whichever occurs first
Detailed description
Change in pulse pressure from baseline to 72h after initiation of ECMO or before cessation of ECMO support, whichever occurs first; ECMO weaning failure, defined as death during ECMO support, death within 24 h after ECMO removal or need for reimplantation of ECMO within 24 h. All cause mortality at 28 days, Urinary output for the first 48 hours post cessation of ECMO support, Central venous saturation at 4, 8, 12, 24 and 48 hours post cessation of ECMO support, Total days requiring ECMO
Interventions
DRUGCernevit
DRUGPulver zur Herstellung einer Injektions- oder einer Infusionslösung
DRUGLevosimendan EQL Pharma 2
DRUG5mg/ml Konzentrat zur Herstellung einer Infusionslösung
Sponsors
Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken, Medical University Of Vienna
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Change in left ventricular outflow tract velocity time integral measured by Doppler echocardiography from baseline to 72h after initiation ECMO or before cessation of ECMO support, whichever occurs first | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in pulse pressure from baseline to 72h after initiation of ECMO or before cessation of ECMO support, whichever occurs first; ECMO weaning failure, defined as death during ECMO support, death within 24 h after ECMO removal or need for reimplantation of ECMO within 24 h. All cause mortality at 28 days, Urinary output for the first 48 hours post cessation of ECMO support, Central venous saturation at 4, 8, 12, 24 and 48 hours post cessation of ECMO support, Total days requiring ECMO | — |
Countries
Austria
Outcome results
None listed